APLS up only 12% on FDA approval of Syfovre (announced after the close on Friday). The modest advance is rational, IMO, because Syfovre simply isn’t that great.
On APLS’ CC Friday evening, executives were touting Syfovre as the one of the greatest breakthroughs in ophthalmology, ever, which I found to be a pretty big turnoff. Please see #msg-171243138 for related info.
Market Data 
Markets 
AI
